Supernus Pharmaceuticals | SUPN - Operating Expenses



Supernus Pharmaceuticals reported $153.31M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Abbott USD 9.07B 369M Jun/2025
ANI Pharmaceuticals USD 196.2M 25.27M Jun/2025
Aurora Cannabis CAD 118.24M 66.26M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Canopy Growth CAD 94.22M 4.36M Jun/2025
Corcept Therapeutics USD 167.76M 13.96M Jun/2025
Eisai JPY 181.91B 7.35B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Novo Nordisk 42.77B 3.48B Jun/2025
Pacira USD 170.87M 3.93M Jun/2025
Perrigo USD 1B 36.2M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Supernus Pharmaceuticals USD 153.31M 892K Jun/2025
United Therapeutics USD 521.7M 110.1M Jun/2025
Xeris Pharmaceuticals USD 67.06M 8.64M Jun/2025